JP2015502134A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015502134A5 JP2015502134A5 JP2014528740A JP2014528740A JP2015502134A5 JP 2015502134 A5 JP2015502134 A5 JP 2015502134A5 JP 2014528740 A JP2014528740 A JP 2014528740A JP 2014528740 A JP2014528740 A JP 2014528740A JP 2015502134 A5 JP2015502134 A5 JP 2015502134A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- pharmaceutical composition
- acid strand
- nucleotides
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 145
- 239000008194 pharmaceutical composition Substances 0.000 claims 101
- 150000007523 nucleic acids Chemical class 0.000 claims 100
- 108020004707 nucleic acids Proteins 0.000 claims 94
- 102000039446 nucleic acids Human genes 0.000 claims 94
- 239000002773 nucleotide Substances 0.000 claims 86
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 15
- 102100034343 Integrase Human genes 0.000 claims 13
- 101710203526 Integrase Proteins 0.000 claims 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 238000002372 labelling Methods 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 3
- 230000003834 intracellular effect Effects 0.000 claims 3
- 238000000746 purification Methods 0.000 claims 3
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 2
- 108091028664 Ribonucleotide Proteins 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 239000002336 ribonucleotide Substances 0.000 claims 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 229930003802 tocotrienol Natural products 0.000 claims 1
- 239000011731 tocotrienol Substances 0.000 claims 1
- 235000019148 tocotrienols Nutrition 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014528740A JP6112569B2 (ja) | 2011-12-16 | 2012-12-17 | キメラ２重鎖核酸 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011275488 | 2011-12-16 | ||
| JP2011275488 | 2011-12-16 | ||
| PCT/JP2012/083180 WO2013089283A1 (en) | 2011-12-16 | 2012-12-17 | Chimeric double-stranded nucleic acid |
| JP2014528740A JP6112569B2 (ja) | 2011-12-16 | 2012-12-17 | キメラ２重鎖核酸 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017044034A Division JP6416301B2 (ja) | 2011-12-16 | 2017-03-08 | キメラ２重鎖核酸 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015502134A JP2015502134A (ja) | 2015-01-22 |
| JP2015502134A5 true JP2015502134A5 (enExample) | 2016-03-31 |
| JP6112569B2 JP6112569B2 (ja) | 2017-04-12 |
Family
ID=47559626
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014528740A Active JP6112569B2 (ja) | 2011-12-16 | 2012-12-17 | キメラ２重鎖核酸 |
| JP2017044034A Active JP6416301B2 (ja) | 2011-12-16 | 2017-03-08 | キメラ２重鎖核酸 |
| JP2018188022A Active JP6638923B2 (ja) | 2011-12-16 | 2018-10-03 | キメラ２重鎖核酸 |
| JP2019224279A Active JP6960123B2 (ja) | 2011-12-16 | 2019-12-12 | キメラ２重鎖核酸 |
| JP2020179738A Active JP7174384B2 (ja) | 2011-12-16 | 2020-10-27 | キメラ２重鎖核酸 |
| JP2021136038A Pending JP2022000426A (ja) | 2011-12-16 | 2021-08-24 | キメラ２重鎖核酸 |
| JP2022146970A Active JP7423015B2 (ja) | 2011-12-16 | 2022-09-15 | キメラ２重鎖核酸 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017044034A Active JP6416301B2 (ja) | 2011-12-16 | 2017-03-08 | キメラ２重鎖核酸 |
| JP2018188022A Active JP6638923B2 (ja) | 2011-12-16 | 2018-10-03 | キメラ２重鎖核酸 |
| JP2019224279A Active JP6960123B2 (ja) | 2011-12-16 | 2019-12-12 | キメラ２重鎖核酸 |
| JP2020179738A Active JP7174384B2 (ja) | 2011-12-16 | 2020-10-27 | キメラ２重鎖核酸 |
| JP2021136038A Pending JP2022000426A (ja) | 2011-12-16 | 2021-08-24 | キメラ２重鎖核酸 |
| JP2022146970A Active JP7423015B2 (ja) | 2011-12-16 | 2022-09-15 | キメラ２重鎖核酸 |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US9816089B2 (enExample) |
| EP (1) | EP2791335B1 (enExample) |
| JP (7) | JP6112569B2 (enExample) |
| CN (2) | CN112386605A (enExample) |
| AU (1) | AU2012353330B2 (enExample) |
| CA (2) | CA3106312C (enExample) |
| ES (1) | ES2707232T3 (enExample) |
| IN (1) | IN2014CN04590A (enExample) |
| WO (1) | WO2013089283A1 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2767253A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc. | Novel nucleic acid prodrugs and methods of use thereof |
| EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| JP6128529B2 (ja) | 2011-07-19 | 2017-05-17 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | 官能化核酸の合成のための方法 |
| CN112386605A (zh) * | 2011-12-16 | 2021-02-23 | 国立大学法人东京医科齿科大学 | 嵌合的双链核酸 |
| US9598458B2 (en) | 2012-07-13 | 2017-03-21 | Wave Life Sciences Japan, Inc. | Asymmetric auxiliary group |
| AU2014222150A1 (en) * | 2013-03-01 | 2015-09-10 | National University Corporation Tokyo Medical And Dental University | Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent |
| WO2014148620A1 (ja) * | 2013-03-21 | 2014-09-25 | 国立大学法人東京医科歯科大学 | 二重鎖核酸結合剤、当該結合剤－二重鎖核酸複合体、当該複合体を含有する医薬品組成物、及び、当該複合体の製造方法 |
| US10190117B2 (en) * | 2013-06-16 | 2019-01-29 | National University Corporation Tokyo Medical And Dental University | Double-stranded antisense nucleic acid with exon-skipping effect |
| WO2015105083A1 (ja) * | 2014-01-07 | 2015-07-16 | 塩野義製薬株式会社 | アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド |
| US9714288B2 (en) | 2014-09-30 | 2017-07-25 | The Regents Of The University Of California | Antisense compounds and uses thereof |
| EP3929293A3 (en) | 2015-04-03 | 2022-03-16 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| US11116843B2 (en) | 2015-09-25 | 2021-09-14 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| WO2017068791A1 (ja) * | 2015-10-23 | 2017-04-27 | レナセラピューティクス株式会社 | 少なくとも１つのバルジ構造を有する核酸複合体 |
| JPWO2017068790A1 (ja) * | 2015-10-23 | 2018-08-09 | レナセラピューティクス株式会社 | 核酸複合体 |
| WO2017094745A1 (ja) * | 2015-12-01 | 2017-06-08 | 国立大学法人大阪大学 | 核酸を含む経腸投与用組成物 |
| JP6988481B2 (ja) | 2016-01-26 | 2022-01-05 | 日産化学株式会社 | 一本鎖オリゴヌクレオチド |
| MA45328A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| JP7043078B2 (ja) * | 2016-09-23 | 2022-03-29 | 国立大学法人 東京医科歯科大学 | 血液脳関門通過型ヘテロ２本鎖核酸 |
| WO2018062510A1 (ja) | 2016-09-29 | 2018-04-05 | 国立大学法人東京医科歯科大学 | オーバーハングを有する二本鎖核酸複合体 |
| CA3052801A1 (en) * | 2017-02-06 | 2018-08-09 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
| US11638717B2 (en) | 2017-03-29 | 2023-05-02 | Shionogi & Co., Ltd. | Complex of nucleic acid medicine and multibranched lipid |
| EP3604531A4 (en) * | 2017-03-31 | 2020-12-23 | Aichi Medical University | NUCLEIC ACID ANTISENS FOR INHIBITION OF CHONDROITIN SULPHATE BIOSYNTHESIS |
| JP6974872B2 (ja) * | 2017-06-30 | 2021-12-01 | 国立大学法人 東京医科歯科大学 | ヘテロ二本鎖型ａｎｔｉｍｉＲ |
| CA3070809A1 (en) | 2017-07-26 | 2019-01-31 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
| US11725208B2 (en) | 2017-12-14 | 2023-08-15 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| US11674141B2 (en) | 2018-02-28 | 2023-06-13 | National University Corporation Tokyo Medical And Dental University | Ischemic-lesion-site-specific gene therapy |
| KR20190110043A (ko) * | 2018-03-19 | 2019-09-27 | 주식회사 케이티 | 비디오 신호 처리 방법 및 장치 |
| EP3769769A4 (en) * | 2018-03-19 | 2022-05-04 | National University Corporation Tokyo Medical and Dental University | NUCLEIC ACID WITH REDUCED TOXICITY |
| CA3094303A1 (en) | 2018-03-20 | 2019-09-26 | Tokyo Institute Of Technology | Antisense oligonucleotide reduced in toxicity |
| EP3770257B1 (en) * | 2018-03-22 | 2026-01-28 | Institute Of Science Tokyo | Bbb-passing lipid ligand of hetero nucleic acid |
| CN113614232A (zh) * | 2019-01-18 | 2021-11-05 | 马萨诸塞大学 | 动态药代动力学修饰锚 |
| JP7687682B2 (ja) * | 2019-04-08 | 2025-06-03 | 国立大学法人東京科学大学 | 筋疾患治療用医薬組成物 |
| EP4005602A4 (en) | 2019-07-30 | 2024-06-12 | Shionogi & Co., Ltd | NUCLEIC ACID AGENT TARGETED AGAINST MURF1 |
| EP4043565A4 (en) * | 2019-10-11 | 2024-01-24 | National University Corporation Tokyo Medical and Dental University | MODIFIED HETERONUCLEIC ACID |
| EP4090744A4 (en) * | 2020-01-17 | 2024-04-10 | Anastasia Khvorova | UNIVERSAL DYNAMIC PHARMACOKINETIC MODIFYING ANCHORS |
| CN114929876A (zh) | 2020-01-31 | 2022-08-19 | 株式会社三和化学研究所 | Atn1的反义寡核苷酸 |
| JPWO2021177418A1 (enExample) | 2020-03-04 | 2021-09-10 | ||
| WO2021187392A1 (ja) | 2020-03-16 | 2021-09-23 | 国立大学法人東京医科歯科大学 | モルホリノ核酸を含むヘテロ核酸 |
| WO2021242883A1 (en) | 2020-05-26 | 2021-12-02 | University Of Massachusetts | Synthetic oligonucleotides having regions of block and cluster modifications |
| JP7751302B2 (ja) | 2020-06-15 | 2025-10-08 | リードファーマ株式会社 | 架橋型ヌクレオシドおよびヌクレオチド |
| WO2022106695A1 (en) | 2020-11-23 | 2022-05-27 | Alpha Anomeric Sas | Nucleic acid duplexes |
| US20240141414A1 (en) * | 2021-02-26 | 2024-05-02 | Northwestern University | Cell-free biosensors with dna strand displacement circuits |
| WO2022250050A1 (ja) | 2021-05-25 | 2022-12-01 | 国立大学法人東京医科歯科大学 | ｓｃｐＢＮＡ又はＡｍＮＡを含むヘテロ核酸 |
| US20240279655A1 (en) | 2021-05-31 | 2024-08-22 | Rena Therapeutics Inc. | Ligand-binding nucleic acid complex |
| EP4389891A4 (en) * | 2021-08-19 | 2025-10-29 | Univ Nat Corp Tokyo Medical & Dental | MODIFIED HETERONUCLEIC ACID CONTAINING MORPHOLINO NUCLEIC ACID |
| JPWO2023026994A1 (enExample) | 2021-08-21 | 2023-03-02 | ||
| WO2023042876A1 (ja) | 2021-09-15 | 2023-03-23 | 国立大学法人東京医科歯科大学 | ２'－修飾ヌクレオシドを含むヘテロ核酸 |
| EP4415827A4 (en) * | 2021-10-14 | 2025-12-03 | Univ Arizona State | PROGRAMMABLE DISTRIBUTION PLATFORMS FOR RNA STRUCTURES |
| JPWO2023080159A1 (enExample) | 2021-11-02 | 2023-05-11 | ||
| JP7412668B2 (ja) * | 2021-12-07 | 2024-01-15 | リードファーマ株式会社 | アンチセンスオリゴヌクレオチド複合体 |
| WO2024071099A1 (ja) | 2022-09-29 | 2024-04-04 | 国立大学法人東京医科歯科大学 | ５'－シクロプロピレン修飾を含む核酸分子 |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| WO2024228398A1 (ja) * | 2023-05-02 | 2024-11-07 | 国立大学法人東京医科歯科大学 | グアニン四重鎖構造を誘導するための核酸剤 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09110894A (ja) * | 1995-10-17 | 1997-04-28 | Soyaku Gijutsu Kenkyusho:Kk | ハイブリッドｄｎａ／ｒｎａオリゴヌクレオチド及び抗ウイルス剤 |
| US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| JP3781879B2 (ja) | 1996-11-18 | 2006-05-31 | 武 今西 | 新規ヌクレオチド類縁体 |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| EP2253639A1 (en) | 1997-09-12 | 2010-11-24 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues |
| US20060074034A1 (en) * | 2001-09-17 | 2006-04-06 | Collins Douglas A | Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof |
| FR2832154B1 (fr) * | 2001-11-09 | 2007-03-16 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene |
| AU2002249967A1 (en) * | 2001-11-12 | 2003-05-26 | Epiclone, Inc. | Gene silencing using sense dna and antisense rna hybrid constructs |
| AU2003247521A1 (en) * | 2002-06-26 | 2004-01-19 | Isis Pharmaceuticals, Inc. | Antisense inhibition via rnase h-independent reduction in mrna |
| DE10240417A1 (de) * | 2002-09-02 | 2004-03-11 | Avontec Gmbh | Decoy-Oligonukleotid-Hemmung der CD40-Expression |
| AU2003273336A1 (en) * | 2002-09-18 | 2004-04-08 | Isis Pharmaceuticals, Inc. | Efficient reduction of target rna's by single- and double-stranded oligomeric compounds |
| EP2336318B1 (en) | 2002-11-13 | 2013-04-24 | Genzyme Corporation | Antisense modulation of apolipoprotein b expression |
| ES2382807T3 (es) | 2003-08-28 | 2012-06-13 | Takeshi Imanishi | Nuevos ácidos nucleicos artificiales del tipo de enlace N-O con reticulación |
| PE20050469A1 (es) * | 2003-09-18 | 2005-09-10 | Lilly Co Eli | Modulacion de la expresion de eif4e |
| US20050244869A1 (en) * | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
| AU2011204898A1 (en) * | 2004-04-09 | 2011-08-11 | Biodelivery Sciences International, Inc | Nucleotide-cochleate compositions and methods of use |
| US20080199960A1 (en) * | 2004-05-13 | 2008-08-21 | Juliano Rudolph L | Methods for the Delivery of Oligomeric Compounds |
| EP1838875A4 (en) * | 2004-12-30 | 2010-08-25 | Todd M Hauser | COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION USING SELF-PROTECTED OLIGONUCLEOTIDES |
| ATE514777T1 (de) | 2006-05-05 | 2011-07-15 | Isis Pharmaceuticals Inc | Verbindungen und verfahren zur modulation von genexpression |
| KR20090064378A (ko) * | 2006-08-10 | 2009-06-18 | 온코세라피 사이언스 가부시키가이샤 | 유방암 관련 유전자 및 폴리펩티드 |
| WO2008029619A1 (fr) | 2006-09-07 | 2008-03-13 | Daiichi Sankyo Company, Limited | Oligonucléotide antisens ena ayant une action spécifique de la séquence |
| ES2603379T3 (es) | 2006-10-09 | 2017-02-27 | Roche Innovation Center Copenhagen A/S | Compuestos antagonistas de ARN para la modulación de PCSK9 |
| US8093222B2 (en) * | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| US7858592B2 (en) * | 2007-02-26 | 2010-12-28 | The Board Of Regents Of The University Of Texas System | Interfering RNAs against the promoter region of P53 |
| US8461124B2 (en) * | 2007-03-15 | 2013-06-11 | Jyoti Chattopadhyaya | Five- and six-membered conformationally locked 2′,4′-carbocyclic ribo-thymidines for the treatment of infections and cancer |
| CN101980726A (zh) * | 2008-02-08 | 2011-02-23 | 普罗森那控股公司 | 治疗与dna重复不稳定性相关的遗传病症的方法和装置 |
| EP2133425A1 (en) | 2008-06-13 | 2009-12-16 | Karin Mölling | Method and compound for antiviral (HIV) therapy |
| US8541569B2 (en) * | 2008-09-06 | 2013-09-24 | Chemgenes Corporation | Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA |
| EP3252068B1 (en) * | 2009-10-12 | 2025-07-02 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
| CN112386605A (zh) * | 2011-12-16 | 2021-02-23 | 国立大学法人东京医科齿科大学 | 嵌合的双链核酸 |
| CA2913499A1 (en) * | 2013-05-30 | 2014-12-04 | National University Corporation Tokyo Medical And Dental University | Double-stranded agents for delivering therapeutic oligonucleotides |
-
2012
- 2012-12-17 CN CN202011292547.5A patent/CN112386605A/zh active Pending
- 2012-12-17 CA CA3106312A patent/CA3106312C/en active Active
- 2012-12-17 JP JP2014528740A patent/JP6112569B2/ja active Active
- 2012-12-17 WO PCT/JP2012/083180 patent/WO2013089283A1/en not_active Ceased
- 2012-12-17 IN IN4590CHN2014 patent/IN2014CN04590A/en unknown
- 2012-12-17 EP EP12815856.5A patent/EP2791335B1/en active Active
- 2012-12-17 CN CN201280062110.XA patent/CN104126010B/zh active Active
- 2012-12-17 ES ES12815856T patent/ES2707232T3/es active Active
- 2012-12-17 AU AU2012353330A patent/AU2012353330B2/en active Active
- 2012-12-17 CA CA2859581A patent/CA2859581C/en active Active
-
2014
- 2014-06-13 US US14/303,989 patent/US9816089B2/en active Active
-
2017
- 2017-03-08 JP JP2017044034A patent/JP6416301B2/ja active Active
- 2017-10-05 US US15/725,845 patent/US10337006B2/en active Active
-
2018
- 2018-06-28 US US16/021,165 patent/US10329567B2/en active Active
- 2018-10-03 JP JP2018188022A patent/JP6638923B2/ja active Active
-
2019
- 2019-05-13 US US16/410,803 patent/US11034955B2/en active Active
- 2019-12-12 JP JP2019224279A patent/JP6960123B2/ja active Active
-
2020
- 2020-10-27 JP JP2020179738A patent/JP7174384B2/ja active Active
-
2021
- 2021-05-27 US US17/332,249 patent/US12344841B2/en active Active
- 2021-08-24 JP JP2021136038A patent/JP2022000426A/ja active Pending
-
2022
- 2022-09-15 JP JP2022146970A patent/JP7423015B2/ja active Active
-
2023
- 2023-12-21 US US18/392,869 patent/US20240158790A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015502134A5 (enExample) | ||
| JP7174384B2 (ja) | キメラ２重鎖核酸 | |
| JP6440170B2 (ja) | キメラ一本鎖アンチセンスポリヌクレオチドおよび二本鎖アンチセンス剤 | |
| US10190117B2 (en) | Double-stranded antisense nucleic acid with exon-skipping effect | |
| JP6472087B2 (ja) | 治療用オリゴヌクレオチドを送達するための二本鎖剤 | |
| CN101535331B (zh) | 人类微小rna以及用于抑制人类微小rna的方法 | |
| JP2014527401A5 (enExample) | ||
| Chistiakov et al. | Strategies to deliver microRNAs as potential therapeutics in the treatment of cardiovascular pathology | |
| JP2016518331A5 (enExample) | ||
| JP2015502365A5 (enExample) | ||
| JP2009535039A5 (enExample) | ||
| JP7560616B2 (ja) | 膜貫通型セリンプロテアーゼ６（ｔｍｐｒｓｓ６）発現を阻害するための組成物および方法 | |
| JP6882735B2 (ja) | 構造強化されたｍｉＲＮＡ阻害剤Ｓ−ＴｕＤ | |
| Sioud | How the initial discovery of modified RNA enabled evasion of innate immune responses and facilitated the development of RNA therapeutics | |
| JP7306653B2 (ja) | 構造強化されたＳ－ＴｕＤを用いた新規がん治療法 | |
| JP2025518507A (ja) | Ｓｎｃａの発現を阻害するための組成物及び方法 | |
| Mehrotra et al. | Therapeutic potential of miRNAs in parasitic infectious diseases | |
| JPWO2021002359A1 (ja) | 核酸医薬とその使用 | |
| US9546364B2 (en) | Synthetic lariat RNA for RNA interference | |
| HK1194764A (en) | Biologically active nucleotide molecules for selectively killing off cells, use thereof, and application kit |